Henry Meds GLP-1vsEden Compounded GLP-1

Henry Meds prescribes compounded versions of GLP-1 receptor agonists, primarily semaglutide (the molecule in Ozempic and Wegovy) and tirzepatide (in Mounjaro and Zepbound). These drugs mimic the gut hormone GLP-1 (tirzepatide also mimics GIP), which slows stomach emptying, signals fullness to the brain, and improves how the body regulates blood sugar and appetite. The result is reduced hunger, smaller portions, and weight loss. "Compounded" means a licensed pharmacy mixes the medication rather than it being a mass-produced, FDA-approved finished product; the FDA has warned that some compounders have used unapproved salt forms (such as semaglutide sodium or acetate) that differ from the base molecule in the approved drugs.

You self-administer a once-weekly subcutaneous injection of compounded semaglutide or tirzepatide. Semaglutide activates GLP-1 receptors; tirzepatide activates both GIP and GLP-1 receptors. The result is slower stomach emptying, increased fullness, and reduced appetite, which lowers calorie intake. An Eden provider sets and titrates the dose over time.

Henry Meds has not published its own clinical trials; efficacy is inferred from studies of the same active molecules. In the pivotal STEP 1 trial (NEJM 2021, 1,961 adults over 68 weeks), once-weekly 2.4 mg semaglutide produced a mean 14.9% reduction in body weight versus 2.4% with placebo, and 86.4% of participants lost at least 5% of their body weight. Tirzepatide produced even larger average losses in its SURMOUNT program. Important caveat: compounded products are not FDA-approved and are not tested for the same bioequivalence, and Henry Meds' lower-strength and oral/sublingual formulations lack the trial evidence that supports the brand injectables, so individual results may differ and could be lower than the trial figures.

Eden's medications share active ingredients with branded drugs studied in major trials: STEP 1 showed branded semaglutide produced roughly 14.9% average weight loss over 68 weeks, and SURMOUNT-1 showed branded tirzepatide produced up to about 20.9% over 72 weeks. Compounded versions are not independently FDA-tested, so these figures are context, not a promise. Individual results vary.

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, which are usually mild-to-moderate and worst during dose escalation. In STEP 1, about 4.5% of semaglutide users discontinued because of GI effects versus 0.8% on placebo. Serious but rarer risks include acute pancreatitis (severe abdominal pain), gallbladder disease, kidney injury from dehydration, and low blood sugar (especially when combined with other diabetes medications). All GLP-1 drugs in this class carry a boxed warning for thyroid C-cell tumors seen in rodents. The FDA has separately flagged compounded products for dosing errors and quality issues, including multiple adverse-event reports, some requiring hospitalization, tied to incorrect self-measured doses.

Gastrointestinal side effects (nausea, constipation, diarrhea) are the most common and usually improve with slow dose titration. Serious but uncommon risks include pancreatitis and gallbladder issues. Because the medication is compounded rather than FDA-approved, report any unexpected symptoms to your provider. This is educational, not medical advice.

As of 2026, Henry Meds compounded injectable semaglutide runs roughly $297/month month-to-month, dropping to about $247/month on a 6-month plan and around $197/month on a 12-month prepay; oral and sublingual options are cheaper (often roughly $99-$249/month), and higher dose tiers typically add about $100/month (some tiers reach about $397/month). The price bundles provider visits, medication, and shipping with no separate membership fee. Compounded GLP-1s are essentially never covered by insurance and are paid out of pocket; by comparison, brand Wegovy or Zepbound can exceed $1,000/month without coverage. Note BBB complaints about auto-renewal billing, unexpected price increases, and refunds, so cancel before renewal and confirm current published pricing at signup.

Plan for $149 the first month and $229/month thereafter for semaglutide, or $249 then $329/month for tirzepatide, as of May 2026. Multi-month bundles cut the effective monthly rate. The price is all-in (visit, medication, free shipping) and is not covered by insurance because the product is compounded.

Generally aimed at adults seeking weight management who meet clinical criteria assessed during the telehealth intake, typically a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, prediabetes, or high cholesterol. You must NOT use these drugs if you or a family member has a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). They are contraindicated in pregnancy and breastfeeding, generally avoided with a history of pancreatitis, and require caution with gallbladder disease, diabetic retinopathy, or severe gastrointestinal disease. Your prescriber makes the final eligibility call. Anyone whose insurance covers FDA-approved Wegovy or Zepbound should weigh those first.

For US adults seeking medical weight management who pass a telehealth clinical review. Not for people with a history of medullary thyroid carcinoma or MEN 2, and not for use in pregnancy. Availability and product options vary by state.